Aprea Therapeutics, Inc. (APRE) — 8-K Filings

8-K Filings (20)

• Aprea Therapeutics Files 8-K — Apr 1, 2026 Risk: low
  Aprea Therapeutics, Inc. filed an 8-K on April 1, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits).
• Aprea Therapeutics Files 8-K: Material Agreements & Equity Sales — Mar 30, 2026 Risk: medium
  On March 30, 2026, Aprea Therapeutics, Inc. filed an 8-K detailing a material definitive agreement and unregistered sales of equity securities. The filing also
• 8-K Filing — Dec 9, 2025
• Aprea Therapeutics Files 8-K — Oct 24, 2025 Risk: low
  Aprea Therapeutics, Inc. filed an 8-K on October 24, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specifi
• Aprea Therapeutics Files 8-K — Oct 15, 2025 Risk: low
  Aprea Therapeutics, Inc. filed an 8-K on October 15, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specifi
• Aprea Therapeutics Files 8-K — Sep 8, 2025 Risk: low
  Aprea Therapeutics, Inc. filed an 8-K on September 8, 2025, reporting other events and financial statements. The company, incorporated in Delaware, has its prin
• Aprea Therapeutics Files 8-K on Shareholder Vote Matters — Jun 9, 2025 Risk: low
  Aprea Therapeutics, Inc. filed an 8-K on June 9, 2025, reporting on a submission of matters to a vote of security holders that occurred on June 5, 2025. The com
• Aprea Therapeutics Files 8-K — Feb 5, 2025 Risk: low
  On February 5, 2025, Aprea Therapeutics, Inc. filed an 8-K report. The filing indicates no specific material events or financial updates were disclosed on this
• Aprea Therapeutics Files 8-K — Jan 13, 2025 Risk: low
  Aprea Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition, as well as other events and financial
• Aprea Therapeutics Files 8-K — Nov 8, 2024 Risk: medium
  Aprea Therapeutics, Inc. filed an 8-K on November 8, 2024, reporting an entry into a material definitive agreement and financial statements. The filing does not
• Aprea Therapeutics Files 8-K — Oct 23, 2024 Risk: low
  Aprea Therapeutics, Inc. filed an 8-K on October 23, 2024, reporting on various events. The filing includes information related to Regulation FD disclosures, ot
• Aprea Therapeutics Files 8-K on Financials and Operations — Oct 9, 2024 Risk: medium
  Aprea Therapeutics, Inc. filed an 8-K on October 9, 2024, reporting on its results of operations, other events, and financial statements. The filing details the
• Aprea Therapeutics Files 8-K on Shareholder Vote Matters — Jun 20, 2024 Risk: low
  Aprea Therapeutics, Inc. filed an 8-K on June 20, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific d
• Aprea Therapeutics Files 8-K — Jun 17, 2024 Risk: low
  Aprea Therapeutics, Inc. filed an 8-K on June 17, 2024, reporting other events and financial statements. The filing does not contain specific details about the
• Aprea Therapeutics Files 8-K — Apr 10, 2024 Risk: low
  On April 10, 2024, Aprea Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicatin
• Aprea Therapeutics Terminates Material Agreement — Mar 12, 2024 Risk: medium
  Aprea Therapeutics, Inc. announced on March 11, 2024, the termination of its material definitive agreement with an unnamed party. The company also disclosed unr
• Aprea Therapeutics Files 8-K for 'Other Events' on Feb 6, 2024 — Feb 6, 2024
  Aprea Therapeutics, Inc. filed an 8-K on February 6, 2024, to report an 'Other Event' and 'Financial Statements and Exhibits.' This filing indicates a routine d
• Aprea Therapeutics Files 8-K on Financial Condition — Feb 2, 2024
  Aprea Therapeutics, Inc. filed an 8-K on February 2, 2024, to report on its 'Results of Operations and Financial Condition.' This filing indicates that the comp
• APRE Files 8-K on Material Definitive Agreement — Jan 26, 2024
  Aprea Therapeutics, Inc. (APRE) filed an 8-K on January 26, 2024, to report an "Entry into a Material Definitive Agreement." This filing indicates a significant
• Aprea Therapeutics Files Routine 8-K on Jan 4, 2024 — Jan 4, 2024
  Aprea Therapeutics, Inc. filed an 8-K on January 4, 2024, reporting 'Other Events' and 'Financial Statements and Exhibits.' This filing indicates standard, rout

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX